2-[3-methoxy-4-(3-o-tolyl-ureido)-phenyl]-N-piperidine-4-ylmethyl-acetamide | 247254-44-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-[3-methoxy-4-(3-o-tolyl-ureido)-phenyl]-N-piperidine-4-ylmethyl-acetamide
• 英文别名: 2-[3-methoxy-4-[(2-methylphenyl)carbamoylamino]phenyl]-N-(piperidin-4-ylmethyl)acetamide
• CAS: 247254-44-0
• 化学式: C₂₃H₃₀N₄O₃
• 分子量: 410.516
• InChiKey: UKLMBGBPCJEYQU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  30
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  91.5
• 氢给体数：
  4
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-[3-methoxy-4-(3-o-tolyl-ureido)-phenyl]-N-piperidine-4-ylmethyl-acetamide 在 sodium hydroxide 、 三乙胺 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 56.0h， 生成 2-Benzyloxycarbonylamino-3-[4-({2-[3-methoxy-4-(3-o-tolyl-ureido)-phenyl]-acetylamino}-methyl)-piperidin-1-yl]-propionic acid
  参考文献：
  名称：

  Diamine containing VLA-4 antagonists

  摘要：

  Design and synthesis of a library as potential VLA-4 antagonists has been accomplished, based around a proposed pharmacophoric model. Compounds possessing submicromolar potency were identified and structure-activity relationships were seen across the library. Further derivatisation produced compounds with IC50'S < 10 nmol for inhibiting the VLA-4 mediated binding of fibronectin to RAMOS cells, providing an ideal starting point for a lead optimisation Programme. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(01)00132-8
• 作为产物：
  描述：

  Tert-butyl 4-[(benzylideneamino)methyl]piperidine-1-carboxylate 在 potassium hydrogensulfate 、 N,N-二异丙基乙胺 、 三氟乙酸 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 生成 2-[3-methoxy-4-(3-o-tolyl-ureido)-phenyl]-N-piperidine-4-ylmethyl-acetamide
  参考文献：
  名称：

  Diamine containing VLA-4 antagonists

  摘要：

  Design and synthesis of a library as potential VLA-4 antagonists has been accomplished, based around a proposed pharmacophoric model. Compounds possessing submicromolar potency were identified and structure-activity relationships were seen across the library. Further derivatisation produced compounds with IC50'S < 10 nmol for inhibiting the VLA-4 mediated binding of fibronectin to RAMOS cells, providing an ideal starting point for a lead optimisation Programme. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(01)00132-8

文献信息

• [EN] SUBSTITUTED DIAMINES AND THEIR USE AS CELL ADHESION INHIBITORS<br/>[FR] DIAMINES SUBSTITUEES ET LEUR UTILISATION EN TANT QU'INHIBITEURS D'ADHESION CELLULAIRE
  申请人：AVENTIS PHARMA LIMITED

  公开号：WO1999054321A1

  公开（公告）日：1999-10-28

  (EN) The invention is directed to physiologically active compounds of general formula (I): wherein R1 represents R5-L3-, R5-L4-R6-, R5-L4-R7-L5-, R5-L4-Ar1-L3-, R5-L4-Ar1-L6-R6- or R5-L4-Ar1-R7-L5-; R2 represents hydrogen or lower alkyl; R3 and R4 independently represent hydrogen or a group selected from alkyl, alkenyl and alkynyl each optionally substituted by one or more atoms or groups chosen from halo, oxo R8, -C(=O)-R9, -NH-C(=O)-R9, or -C(=O)NY1Y2; or R3 and R4 together may represent -(CH2)n- or C(=O)-CH=CH-; L1 represents C2-6alkylene or formula (II); or the group -L1-N(R3)- represents formula (III); or the group -N(R2)-L1- represents formula (IV); or the group -N(R2)-L1-N(R3)- represents formula (V); L2 represents an alkylene, alkenylene, alkynylene, cycloalkenylene, cycloalkylene or heterocycloalkylene linkage, each optionally substituted by alkyl, alkenyl, alkynyl, aryl, carboxy (or an acid bioisostere), cyano, cycloalkenyl, cycloalkyl, heteroaryl, heterocycloalkyl, oxo, -C(=O)R9, -C(=O)OR9, -C(=O)NY1Y2 or -NY1Y2, or by alkyl substituted by aryl, carboxy (or an acid bioisostere), cyano, heteroaryl, heterocycloalkyl, hydroxy, mercapto, -C(=O)R9, -C(=O)OR9, -C(=O)NY1Y2, -OR9, S(O)vR9, -NHC(=O)Oalkyl, -NY1Y2, -NR10C(=Z)-NY3Y4 or -NH-C(=NH)NH2; or the group -N(R4)-L2- represents formula (VI); Y is carboxy (or an acid bioisostere) or -C(=O)-NY1Y2; and m is zero or 1; and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs. Such compounds have valuable pharmaceutical properties, in particular the ability to regulate the interaction of VCAM-1 and fibronectin with the integrin VLA-4($g(a)4$g(b)1).(FR) La présente invention concerne des composés physiologiquement actifs de formule générale (I) dans laquelle R1 représente R5-L3-, R5-L4-R6-, R5-L4-R7-L5-, R5-L4-Ar1-L3, R5-L4-Ar1-L6-R6- ou R5-L4-Ar1-R7-L5-; R2 représente l'hydrogène ou un alkyle inférieur; R3 et R4 représentent indépendamment l'hydrogène ou un groupe pris dans alkyle, alcényle et alkynyl, chacun pouvant être substitués par un ou plusieurs atomes ou groupes choisis dans halo, oxo, R8, -C(=O)-R9, -NH-C(=O)-R9 ou -C(=O)NY1Y2; ou R3 et R1 ensemble peuvent représenter -(CH2)n- ou-C(=O)-CH=CH-; L1 représente C2-6 alkylène ou (II); ou le groupe -L1-N(R3)- représente (III); ou le groupe -N(R2)-L1- représente (IV); ou le groupe N(R2)-L1-N(R3) représente (V); L2 représente une liaison alkylène, alkénylène, alkynylène, cycloalkénylène, cycloalkylène ou hétérocycloalkylène, chacune éventuellement substituée par alkyle, alcényle, alkynyle, aryle, carboxy (ou un acide bioisostère), cyano, cycloalcényle, cycloalkyle, hétéroaryle, hétérocycloalkyle, oxo, -C(=O)R9, -C(=O)OR9, -C(=O)NY1Y2 ou NY1Y2, ou par alkyle substitué lui-même par aryle, carboxy (ou acide un bioisostère), cyano, hétéroaryle, hétérocycloalkyle, hydroxy, mercapto, -C(=O)R9, C(=O)OR9, C(=O)NY1Y2, -OR9, S(O)vR9, -NHC(=O)Oalkyle, -NY1Y2, -NR10C(=Z)-NY3Y4 ou -NH-C(=NH)NH2; ou le groupe -N(R4)-L2 représente (VI); Y est carboxy (ou un acide bioisostère) ou -C(=O)-NY1Y2; et m est zéro ou 1. L'invention concerne également les promédicaments ainsi que les sels et solvats pharmaceutiquement acceptables de ces composés et de leurs promédicaments. Ces composés possèdent des propriétés pharmaceutiques précieuses, en particulier l'aptitude à réguler l'interaction de VCAM-1 et de la fibronectine avec l'intégrine VLA-4($g(a)4$g(b)1).

  本发明涉及一般式(I)的生理活性化合物，其中R1代表R5-L3-、R5-L4-R6-、R5-L4-R7-L5-、R5-L4-Ar1-L3-、R5-L4-Ar1-L6-R6-或R5-L4-Ar1-R7-L5-；R2代表氢或低级烷基；R3和R4分别代表氢或从烷基、烯基和炔基中选择的一个基团，每个基团可以选择一个或多个原子或基团，包括卤素、氧代R8、-C（=O）-R9、-NH-C（=O）-R9或-C（=O）NY1Y2；或R3和R4在一起可以表示-(CH2)n-或C（=O）-CH=CH-；L1表示C2-6烷基或式(I)；或者-L1-N（R3）-表示式(III)；或者-N（R2）-L1-表示式(IV)；或者-N（R2）-L1-N（R3）-表示式(V)；L2表示一种烷基、烯基、炔基、环烯基、环烷基或杂环烷基链，每个链可以选择烷基、烯基、炔基、芳基、羧基（或酸生物同位素）、氰基、环烯基、环烷基、杂环芳基、杂环烷基、氧代、-C（=O）R9、-C（=O）OR9、-C（=O）NY1Y2或-NY1Y2，或者通过芳基、羧基（或酸生物同位素）、氰基、杂环芳基、杂环烷基、羟基、巯基、-C（=O）R9、-C（=O）OR9、-C（=O）NY1Y2、-OR9、S（O）vR9、-NHC（=O）O烷基、-NY1Y2、-NR10C（=Z）-NY3Y4或-NH-C（=NH）NH2取代的烷基取代；或者-N（R4）-L2-表示式(VI)；Y代表羧基（或酸生物同位素）或-C（=O）NY1Y2；m为零或1；以及这些化合物及其前药、药用可接受的盐和溶剂。这些化合物具有有价值的药理特性，特别是调节VCAM-1和纤维连接蛋白与整合素VLA-4（α4β1）相互作用的能力。
• Diamine containing VLA-4 antagonists
  作者：Peter C. Astles、Neil V. Harris、Andrew D. Morley

  DOI：10.1016/s0968-0896(01)00132-8

  日期：2001.8

  Design and synthesis of a library as potential VLA-4 antagonists has been accomplished, based around a proposed pharmacophoric model. Compounds possessing submicromolar potency were identified and structure-activity relationships were seen across the library. Further derivatisation produced compounds with IC50'S < 10 nmol for inhibiting the VLA-4 mediated binding of fibronectin to RAMOS cells, providing an ideal starting point for a lead optimisation Programme. (C) 2001 Elsevier Science Ltd. All rights reserved.